Immediate and Near Future Prediction of COVID-19 Patients in the U.S. Population Aged 65+ With the Prior Medical Conditions of Hypertension, Cardiovascular and Lung Diseases: Methods, Models and Acute Care Estimates

Arni S.R. Srinivasa Rao,Ph.D.[a],*
Douglas D. Miller,MD, CM, MBA[b]
Adam E. Berman,MD, MSc.,MPH[c]
David C. Hess,MD[d]
Steven G. Krantz,Ph.D.[e]

[a] Professor, Division of Health Economics and Modeling, Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, USA.
Director, Laboratory for Theory and Mathematical Modeling, Division of Infectious Diseases, Department of Medicine, Medical College of Georgia, Augusta, GA 30912, USA.
Professor, Department of Mathematics, Augusta University, Augusta, GA 30912.
*Corresponding author
(email: arrao@augusta.edu)
[b] Vice Dean and Professor of Medicine (Cardiology), Radiology and Population Health Sciences. Medical College of Georgia, Augusta University; Augusta, GA. USA.
[c] Professor of Medicine (Cardiology), Pediatrics, and Population Health Sciences.
Chief, Division of Health Economics and Modeling, Department of Population Health Sciences. Medical College of Georgia. Augusta University; Augusta, GA. USA.
[d] Dean and Professor, Department of Neurology, Medical College of Georgia, Augusta University, Augusta, GA 30912
[e] Professor, Department of Mathematics, Washington University in St. Louis, Campus Box 1146, One Brookings Drive, St. Louis, Missouri 63130, USA.

Abstract

Importance: Given the rapid rise of COVID-19 cases in the U.S. during March 2020 there has been a severe burden on the health care systems and care providers in the country. The impact of the virus so far was higher on the population aged 65+. Hospitalizations were higher among those with underlying medical conditions, namely, hypertension, cardiovascular and lung diseases. Hence, to have an idea of the number of new COVID-19 infections among these high-risk populations that could occur in the short-term could assist promptly to the country's health care system for immediate health care planning. These estimates may aid us in better understanding the potential volumes of patients requiring inpatient care.

Objective: To provide immediate and short-term model-based predictions of COVID-19 patients in the U.S. population aged 65+ during April-June, 2020, those with the prior medical conditions of hypertension, cardiovascular and lung diseases.

Design, Setting, and Participants: We developed age-structured dynamic mathematical combined with wavelet analysis to understand the number of new cases that may emerge in the U.S. population aged 65+. We have estimated the number of people aged 65+ who might have three underlying conditions mentioned and a possible number of hospitalizations among them due to COVID-19 if they get infected. We have used publicly available data sources for developing our framework and estimates.

Results: We estimate that there are 13 million individuals aged 65+ who have one or a combination of three major prior medical conditions in the U.S. who need to be protected against COVID-19 to reduce a large number of hospitalizations and associated deaths. Hospitalizations of patients both with and without ICU-admissions with more prevalent underlying conditions could range between 31,633 (20,310 non-ICU hospitalizations and 11,323 ICU-admissions) to 94,666 (60,779 non-ICU hospitalizations and 33,866 ICU-admissions) cases during the same period. Under a rapid spread of the virus environment, these hospitalizations could be beyond 430,000 within the above three-month period.

Conclusions and Relevance: COVID-19 continues to dramatically and adversely affect the lives of people aged 65+ in the U.S. During the next three months which could result in thousands of hospitalizations if precautions against the virus spread are not implemented and adhered to.

Key words: SARS-Cov-2, predicted hospitalizations, wavelets, dynamic models, multi morbidity, comorbidity

Introduction

The novel coronavirus, SARS-Cov-2, is the agent responsible for COVID-19, and has caused more than 10,000 hospitalizations within a short period since the first case was detected in the U.S. on January 20, 2020, in a returned traveler from Wuhan, China. On February 26th, the CDC (Centers for Disease Control and Prevention) reported the first case from a person who had no travel history or no known contact with an infected individual [1]. As of April 10, 2020, the number of reported cases in the U.S. is 505,015 with more than 18,771 deaths and 29,000 recovered cases. Globally, there have been more than 1.7 million people infected as of April 10, 2020, with 104,000 deaths.

CDC derived hospitalization data on COVID-19 patients in the U.S. demonstrates that 89.3% of affected individuals had underlying conditions [2]. The most common of these underlying conditions were hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%). A MMWR report released by CDC on April 3, 2020 [3] indicates that among U.S. adults aged 19+ who were hospitalized due to COVID-19 through March 28, 2020, almost 60% were of age 65+ who were reported to have one or more underlying medical condition. Some of these hospitalizations resulted in admission into an Intensive Care Unit (ICU) setting. In the April 8th MMWR report [2], it was mentioned that among the U.S. COVID-19 cases aged 65+, the most prevalent prior conditions were hypertension (72.6%), cardiovascular diseases (50.8%), diabetes (45%) and lung diseases (38.7%). Eighty percent of the U.S. COVID-19 related deaths reported through March 16th were aged 65+ [4]. Several other U.S. and international research studies have indicated COVID-19 has a strong association with older adults requiring hospitalization if they also possessed any prior underlying medical condition [5-11].

2

Considering the importance of infections among older adults, especially those aged 65+ who exhibit a higher probability of hospitalization if becoming infected with COVID-19, we undertook our study to predict the possible number of people in this age group who might become infected during next three months (April-June, 2020) in the U.S. We aim to provide these predictions with a breakdown of the possible number of patients who also exhibit the underlying comorbidities of hypertension, cardiovascular diseases, and lung diseases. We developed mathematical methods and dynamic models to predict the number of persons who might be COVID-19 infected between April 7 and June 30, 2020. Our previous modeling work on COVID-19 has contributed important finding on under-reporting in the U.S. and in other countries [12-13], policy frameworks [14]. Our COVID-19 research has also contributed to the development of deeper mathematical methods for obtaining true epidemic growth through wavelet functions [15] and artificial intelligence modeling frameworks for identification of COVID-19 [16]. Details on the methods developed, models, and the data are provided in the Appendix. We have provided three sets of model-based predictions, namely, lower, medium and higher, with corresponding numbers of underlying medical conditions in the U.S. among aged 65+.

Key findings

We predict that there will be at least 34,000 to 104,000 more infections among the U.S. 65+ year old population during April 7 and June 30, 2020. This range could extend to 470,000 more infections due to higher transmission rates if insufficient

precautions against the spread of the virus are implemented (**Figure 1**).

Figure 1. Predicted Monthly new COVID-19 Patients in the U.S. Population aged 65+ during April–June, 2020.

Our predictions on hospitalizations during this period of people aged 65+ range between 31,000 to 94,000. Under a relaxed spread environment, these hospitalizations could be beyond 430,000 within the above three-month period. See the breakdown of these hospitalization numbers with and without ICU-admissions in **Figure 2** and **Table 2.**

Our predicted hospitalizations with a breakdown of underlying conditions indicate that there will be at least 25,259 (9,972 non-ICU and 5,439 ICU) hospitalizations of hypertension-related, 17,674 (6,977 non-ICU and 3,806 ICU) of cardiovascular disease-related, and 13,465 (3,361 non-ICU and 2,078 ICU) cases of lung diseases related hospitalizations during April 7 and June 30, 2020. These hospitalization numbers for medium-range predictions are 75,000, 53,000

3

and 40,000 for hypertension, cardiovascular and lung disease-related, respectively. **Table 2** provides further details of these estimates, including the composition of a potential worst-case scenario.

Our predicted hospitalizations with a breakdown of underlying conditions indicate that there will be at least 15,400 cases of hypertension-related, 10,700 cases of cardiovascular disease-related, and 5,400 cases of lung diseases related hospitalizations during April 7 and June 30, 2020. These hospitalization numbers for medium-range predictions are 46,000, 32,000 and 16,000 for hypertension, cardiovascular and lung disease-related, respectively. **Table 2** provides further details of these estimates, including the composition of a potential worst-case scenario.

We have demonstrated the magnitude of the difference between various underlying conditions using (Yves) Meyer's wavelets, which are very flexible to capture within a broader spectrum of values. Meyer wavelets are a Fourier transformation of a scaling function, useful for multi-fault classification based on signal decomposition levels using wavelet analysis and support vector machine learning (**Figure 3**).

Conclusions

COVID-19 continues to dramatically and adversely affect the lives of people aged 65+ in the U.S. During the next three months which could result in thousands of hospitalizations if precautions against the virus spread are not implemented and adhered to. When evaluating death rates attributable to COVID-19, it is

important to separate hospitalizations caused solely by COVID-19 from hospitalizations caused by other illnesses and underlying conditions. This information is important for epidemiological and public health planning purposes, and also for a full understanding of the spread of the disease. Our predictions will be useful in providing state level predictions so that more in-depth prevention measures may be developed and implemented.


Figure 2. Predicted hospitalizations with and without ICU admissions during April-June, 2020 among the U.S. population aged 65+.


Figure 3. Meyer's wavelets of number of predicted prior conditions among COVID-19 patients in the U.S. population aged 65+ during April – June, 2020.

References:

1. CDC, the COVID-19 Cases in the U.S. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html#2019coronavirus-summary (accessed on April 9, 2020).

2. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep*. ePub: 8 April 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6915e3external icon.

3. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:382–386.

4. CDC COVID-19 Response Team, Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6912e2-H.pdf (Accessed on April 6, 2020).

5. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, Jain SS, Burkhoff D, Kumaraiah D, Rabbani L, Schwartz A and Uriel N. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. *Circulation.* 2020. doi: 10.1161/CIRCULATIONAHA.120.046941.

6. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. *JAMA Cardiol*. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1286doi:10.1001/jamacardio.2020.0950

7. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1017

8. Tackling COVID-19: Health, Quarantine and Economic Measures of South Korea, Development Finance Bureau at Ministry of Economy and Finance, Korea Centers for Disease Control & Prevention (KCDC) and Ministry of Health and Welfare (MOHW)

9. Roxby AC, Greninger AL, Hatfield KM, et al. Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults — Seattle, Washington, 2020. *MMWR Morb Mortal Wkly Rep*. ePub: 3 April 2020.

10. Coronavirus Threatens Americans With Underlying Conditions, NY Times (accessed on April 7, 2020).

11. COVID-19 and Hypertension https://www.lark.com/blog/coronavirus-and-hypertension/ (Accessed on April 7, 2020)

12. Krantz, S.G, & Rao, A.S.R.S (2020). Level of under-reporting including under-diagnosis before the first peak of COVID-19 in various countries: Preliminary Retrospective Results Based on Wavelets and Deterministic Modeling. *Infection Control & Hospital Epidemiology*, 1-8. doi:10.1017/ice.2020.116

13. Rao, A.S.R.S, Krantz S.G., Kurien T, Bhat, R, Sudhakar K (2020). Model-Based Retrospective Estimates for COVID-19 or Coronavirus in India: Continued Efforts Required to Contain the Virus Spread, *Current Science, 118, 7: 1023-1025.*

14. Krantz, S.G, & Rao, A.S.R.S (2020). Preparedness and Response within Individual G7 Countries for COVID-19: Was there a Failure, in Spite of U. S. Economic Strength, of Health Intelligence in the U.S. to Assess the Prior Situation?

https://www.imagwiki.nibib.nih.gov/resources/publications/preparedness-and-response-within-individual-g7-countries-covid-19-was-there (Accessed on April 7, 2020).

15. Krantz S.G., Polyakov P.G. Rao, A.S.R.S. (2020). True epidemic growth construction through harmonic analysis. *Journal of Theoretical Biology* (Elsevier). Volume 494, 7 June 2020, 110243

16. Rao, A.S.R.S, & Vazquez, J.A (2020). Identification of COVID-19 Can be Quicker through Artificial Intelligence framework using a Mobile Phone-Based Survey in the Populations when Cities/Towns Are Under Quarantine. *Infection Control & Hospital Epidemiology*, 1-18. doi:10.1017/ice.2020.61

17. C.T. Bauch, Arni S.R. Srinivasa Rao, B.Z. Pham, M. Krahn, V. Gilca, B. Duval, M.H. Chen, A.C. Tricco,A dynamic model for assessing universal Hepatitis A vaccination in Canada,Vaccine,Volume 25, Issue 10,2007,Pages 1719-1726.

18. Amariei, R., Willms, A.R. & Bauch, C.T. The United States and Canada as a coupled epidemiological system: An example from hepatitis A. BMC Infect Dis 8, 23 (2008). https://doi.org/10.1186/1471-2334-8-23

19. Pham, B., Chen, M. H., Tricco, A. C., Anonychuk, A., Krahn, M., & Bauch, C. T. (2012). Use of a Catalytic Model to Estimate Hepatitis A Incidence in a Low-Endemicity Country: Implications for Modeling Immunization Policies. Medical Decision Making, 32(1), 167–175. https://doi.org/10.1177/0272989X11398489

20. Rao A.S.R.S (2014). Population stability and momentum. *Notices of the American Mathematical Society* 9, 1062-1065

21. Rao, A.S.R.S. and JR Carey (2019). On the Three Properties of Stationary Populations and knotting with Non-Stationary Populations, *Bulletin of Mathematical Biology* (Springer) 81 (10), 4233-4250

22. Rao, A.S.R.S, Chen, M.H., Pham, B.Z. et al. Cohort effects in dynamic models and their impact on vaccination programmes: an example from Hepatitis A. BMC Infect Dis 6, 174 (2006). https://doi.org/10.1186/1471-2334-6-174

23. Mubayi A (2017). Inferring patterns, dynamics, and model-based metrics of epidemiological risks of neglected tropical diseases, *Handbook of statistics* 37, 155-183

24. C Castillo-Chavez, HW Hethcote, V Andreasen, SA Levin, WM Liu (1989). Epidemiological models with age structure, proportionate mixing, and cross-immunity Journal of mathematical biology 27 (3), 233-258.

25. Rao, A. S. R. S., Thomas, K., Sudhakar, K., & Maini, P. K. (2009). HIV/Aids epidemic in India and predicting the impact of the national response: mathematical modeling and analysis. *Mathematical Biosciences and Engineering* 4: 779-813

26. Anderson, R., May, R. Population biology of infectious diseases: Part I. Nature 280, 361–367 (1979). https://doi.org/10.1038/280361a0

27. Kakehashi M (1998). A mathematical analysis of the spread of HIV/AIDS in Japan, *Mathematical Medicine and Biology: A Journal of the IMA*, Volume 15, Issue 4, December 1998, Pages 299–311, https://doi.org/10.1093/imammb/15.4.299

28. G Chowell, PW Fenimore, MA Castillo-Garsow, C Castillo-Chavez (2003). SARS outbreaks in Ontario, Hong Kong and Singapore: the role of diagnosis and isolation as a control mechanism Journal of theoretical biology 224 (1), 1-8.

29. Rao, A. S. R. S (2008). Modeling the rapid spread of avian influenza (H5N1) in India. *Mathematical biosciences and engineering*: MBE 5 (3), 523

30. Rao, A.S.R.S and Anderson, R.M. (2017). Helminth Dynamics: Mean Number of Worms, Reproductive Rates. *Handbook of statistics* 36, 397-404.

31. Krantz S.G. (1999). *A Panorama of Harmonic Analysis*, Carus Mathematical Monographs, 27, Mathematical Association of America, Washington.

32. Hernández, E, Weiss G(1996). *A First Course on Wavelets*, CRC Press, LLC

33. Meyer Y. (1998). *Wavelets, Vibrations and Scalings*. With a preface in French by the author. CRM Monograph Series, 9, American Mathematical Society, Providence, RI.

34. Labate, D, Weiss, G, Wilson, E (2013). Wavelets. *Notices Amer. Math. Soc.*, 60, pp. 66-76.

35. Meyer, Y, Ryan, R.D. (1993). *Wavelets: Algorithms and Applications*. Society for Industrial and Applied Mathematics, Philadelphia.

36. Ritchey MD, Wall HK, Owens PL, Wright JS. Vital Signs: State-Level Variation in Nonfatal and Fatal Cardiovascular Events Targeted for Prevention by Million Hearts 2022. MMWR *Morb Mortal Wkly Rep* 2018;67:974–982. DOI: http://dx.doi.org/10.15585/mmwr.mm 6735a3external icon. (Assessed on April 5, 2020).

37. Rodriguez, F.H., III, Moodie, D.S., Parekh, D.R., Franklin, W.J., Morales, D.L., Zafar, F., Adams, G.J., Friedman, R.A. and Rossano, J.W. (2013), Adult Congenital Heart Disease Heart Failure. Congenit Heart Dis, 8: 513-519. doi:10.1111/chd.12019

38. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States, Health Aff, 2007, vol. 26(pg. 38-48)

39. Krishnamurthi N, Francis J, Fihn SD, Meyer CS, Whooley MA (2018) Leading causes of cardiovascular hospitalization in 8.45 million US veterans. PLoS ONE 13(3): e0193996. https://doi.org/10.1371/journal.pone.0 193996 pmid:29566396

40. Jing Fang, George A. Mensah, Janet B. Croft, Nora L. Keenan,Heart Failure-Related Hospitalization in the U.S., 1979 to 2004,Journal of the American College of Cardiology,Volume 52, Issue 6,2008,Pages 428-434.

41. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure–associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61(12):1259–1267. doi:10.1016/j.jacc.2012.12.038

42. Chang, P. P., Wruck, L. M., Shahar, E., Rossi, J. S., Loehr, L. R., Russell, S. D., Agarwal, S. K., Konety, S. H., Rodriguez, C. J., & Rosamond, W. D. (2018). Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005–2014) ARIC study community surveillance. Circulation, 138(1), 12-24. https://doi.org/10.1161

43. Bansal, N.; Zelnick, L.; Bhat, Z.; Dobre, M.; He, J.; Lash, J.; Jaar, B.; Mehta, R.; Raj, D.; Rincon-Choles, H.; et al. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. J. Am. Coll. Cardiol. 2019, 73, 2691–2700.

44. Profile of Older Americans (2017). https://acl.gov/sites/default/files/Aging %20and%20Disability%20in%20Ame rica/2017OlderAmericansProfile.pdf (Assessed on April 5, 2020).

45. The World Bank Open Data. https://data.worldbank.org/ (accessed on April 5, 2020)

46. https://www.worldometers.info/coronavirus/#countries (Access on March 24, 2020)

47. Selected health conditions and risk factors, by age: United States, selected years 1988–1994 through 2015–2016, CDC Table https://www.cdc.gov/nchs/data/hus/2018/021.pdf (Accessed on April 7, 2020)

48. Burt VL, Whelton P, Roccella EJ. et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-3137875754

49. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-40415326093

50. Zhang D, Wang G, Zhang P, Fang J, Ayala C. Medical Expenditures Associated With Hypertension in the U.S., 2000-2013. Am J Prev Med. 2017;53(6S2):S164–S171. doi:10.1016/j.amepre.2017.05.014

51. Park, S, Gillespie, C, Baumgardner, J, et al. Modeled state-level estimates of hypertension prevalence and undiagnosed hypertension among US adults during 2013-2015. J Clin Hypertens. 2018; 20: 1395– 1410. https://doi.org/10.1111/jch.13388

52. Henning Gall, Marius M. Hoeper, Manuel J. Richter, William Cacheris, Barbara Hinzmann, Eckhard MayerAn epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan, European Respiratory Review Mar 2017, 26 (143) 160121; DOI: 10.1183/16000617.0121-2016

53. Noam Y. Kirson, Howard G. Birnbaum, Jasmina I. Ivanova, Tracy Waldman, Vijay Joish & Todd Williamson (2011) Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States, Current Medical Research and Opinion, 27:9, 1763-1768, DOI: 10.1185/03007995.2011.604310

54. R.M. Pandey, R. Gupta, A. Misra, et al.Determinants of urban-rural differences in cardiovascular risk factors in middle-aged women in India: a cross-sectional studyInt J Cardiol, 163 (2) (2013), pp. 157-162, 10.1016/j.ijcard.2011.06.008

55. Adeloye D Basquill C Aderemi AV Thompson JY Obi FAAn estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis.J Hypertens. 2015; 33: 230-242

56. Qin X., Jackson R., Marshall R., et al.(2009) Modelling the potential impact of population-wide and targeted high-risk blood pressure-lowering strategies on cardiovascular disease in China. Eur J Cardiovasc Prev Rehabil 16:96–101.

57. Niiranen TJ, Jula AM, Kantola IM, Reunanen A . Prevalence and determinants of isolated clinic hypertension in the finnish population: the Finn-HOME study. J Hypertens 2006; 24: 463–470.

58. R. J. Halbert, J. L. Natoli, A. Gano, E. Badamgarav, A. S. Buist, D. M. Mannino (2006). Global burden of COPD: systematic review and meta-analysis European Respiratory Journal Sep 2006, 28 (3) 523-532; DOI: 10.1183/09031936.06.00124605

59. Yeatts KB, Lippmann SJ, Waller AE, et al. Population-based burden of COPD-related visits in the ED: return ED visits, hospital admissions, and comorbidity risks. Chest. 2013;144(3):784–793. doi:10.1378/chest.12-1899

60. Rui P, Kang K. National Hospital Ambulatory Medical Care Survey: 2017 emergency department summary tables. National Center for Health Statistics: https://www.cdc.gov/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf (accessed on April 6, 2020)

61. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34(5):575–584. doi:10.1016/j.cjca.2017.12.005

62. Rahman, M., Zaman, M., Islam, J. et al. Prevalence, treatment patterns, and risk factors of hypertension and pre-hypertension among Bangladeshi adults. J Hum Hypertens 32, 334–348 (2018).

https://doi.org/10.1038/s41371-017-0018-x

63. Morrissey KComorbidity and healthcare use for individuals with CVD in the Ireland: a cross-sectional, population-based studyBMJ Open 2019;9:e025305. doi: 10.1136/bmjopen-2018-025305

64. Mahishale V, Angadi N, Metgudmath V, Eti A, Lolly M, Khan S. Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: A hospital-based cross-section study. J Transl Int Med. 2015;3(4):155–160. doi:10.1515/jtim-2015-0019

65. Global Burden of Cardiovascular Diseases Collaboration. The Burden of Cardiovascular Diseases Among US States, 1990-2016. JAMA Cardiol. 2018;3(5):375–389. doi:10.1001/jamacardio.2018.0385

66. Mathur R,Hull SA, Badrick E, Robson J (2011). Cardiovascular multimorbidity: the effect of ethnicity on prevalence and risk factor management, British Journal of General Practice 2011; 61 (586): e262-e270. DOI: 10.3399/bjgp11X572454

67. Park C, Fang J, Hawkins NA, Wang G. Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults. Am J Prev Med. 2017;53(6S2):S172–S181. doi:10.1016/j.amepre.2017.07.014

68. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099–2107.

69. van Manen JG, Bindels PJ, IJzermans CJ., van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001;54:287–293.

70. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068–2075.

71. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000;160:2653–2658.

72. VF Corrales-Medina, DM Musher, GA Wells, JA Chirinos, L Chen, MJ FineCardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality, Circulation, 125 (2012), pp. 773-781

73. S. Van Eeden, J. Leipsic, S.F. Paul Man, D.D. SinThe relationship between lung inflammation and cardiovascular diseaseAm J Respir Crit Care Med, 186 (2012), pp. 11-16

74. Mette Thomsen, Morten Dahl, Peter Lange, Jørgen Vestbo, Børge G. Nordestgaard. (2012) Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 186:10, 982-988.

75. Baskaran V, Murray RL, Hunter A. et al Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. PLoS One 2019; 14: e0220204 . doi:10.1371/journal.pone.0220204

76. Yeh JJ, Lin CL, Kao CH. Relationship between pneumonia and cardiovascular diseases: a retrospective cohort study of the general population. Eur J Intern Med. 2018 [cited 2018 Aug 8]. DOI: 10.1016/j.ejim.2018.08.003

77. H. Kankaanranta, P. Kauppi, L.E. Tuomisto, P. IlmarinenEmerging comorbidities in adult asthma: risks, clinical associations, and mechanismsMediat. Inflamm., 2016 (2016), p. 3690628

78. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024 doi: 10.1093/ofid/ofu024

79. Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up.Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SRBMJ. 2017 Feb 13; 356():j413.

80. Bornheimer R, Shea KM, Sato R, Weycker D, Pelton SI. Risk of exacerbation following pneumonia in adults with heart failure or chronic

obstructive pulmonary disease. PLoS One. 2017;12(10):e0184877. Published 2017 Oct 13. doi:10.1371/journal.pone.0184877

81. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264–274. doi:10.1001/jama.2014.18229

82. Perry TW, Pugh MJ, Waterer GW, et al. Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med. 2011;124(3):244–251. doi:10.1016/j.amjmed.2010.11.014

83. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. Int J Infect Dis. 2013;17:e1125–9. PMID:24007923, http://dx.doi.org/10.1016/j.ijid.2013.07.005.Return to ref 17 in article

84. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance–United States, 1971–2000. MMWR Surveill Summ 2002;51:1–16.Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance–United States, 1971–2000. MMWR Surveill Summ 2002;51:1–16.

85. D. M. Mannino, D. Thorn, A. Swensen, F. Holguin, Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD European Respiratory Journal 2008 32: 962-969; DOI: 10.1183/09031936.00012408

86. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005–2011.

87. Antonelli-Incalzi R, Fuso L, DeRosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794–2800.

88. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–555. doi:10.1513/pats.200709-148ET

89. Park C, Fang J, Hawkins NA, Wang G. Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults. Am J Prev Med. 2017;53(6S2):S172–S181. doi:10.1016/j.amepre.2017.07.014

90. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease. JAMA. 2015;313(3):264–274. doi:10.1001/jama.2014.18229

91. Duffy S, Barnett S, Civic B, Mamary AJ, Criner GJ. Risk of death by comorbidity prompting rehospitalization following the initial COPD hospitalization. J COPD F. 2015; 2(1): 17-22. doi: http://doi.org/10.15326/jcopdf.2.1.2014.0129

92. Ongel E, Karakurt Z, Salturk C, Takir H, Burunsuzoglu B, Kargin F, Ekinci G, Mocin O, Gungor G, Adiguzel N, Yilmaz A. How do COPD comorbidities affect ICU outcomes?. Int J Chron Obstruct Pulmon Dis. 2014;9(1):1187-1196

93. Yin HL, Yin SQ, Lin QY, Xu Y, Xu HW, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis. Medicine (Baltimore). 2017;96(19):e6836. doi:10.1097/MD.0000000000006836

94. Frits M.E. Franssen, Carolyn L. RochesterComorbidities in patients with COPD and pulmonary rehabilitation: do they matter? European Respiratory Review Mar 2014, 23 (131) 131-141; DOI: 10.1183/09059180.00007613

95. Crisafulli E, Costi S, Luppi F, et alRole of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitationThorax 2008;63:487-492.

96. Ishigami K, Okuro M, Koizumi Y, et al. Association of severe hypertension with pneumonia in elderly patients with acute ischemic stroke. Hypertens Res. 2012;35(6):648–653. doi:10.1038/hr.2012.7

97. Hyman D.J.Pavlik V.N. Characteristics of patients with uncontrolled hypertension in the United States.New Engl. J. Med. 2001; 345: 479-486

98. Julio A Ramirez, Timothy L Wiemken, Paula Peyrani, Forest W Arnold, Robert Kelley, William A Mattingly, Raul Nakamatsu, Senen Pena, Brian E Guinn, Stephen P Furmanek, Annuradha K Persaud, Anupama Raghuram, Francisco Fernandez, Leslie Beavin,

Rahel Bosson, Rafael Fernandez-Botran, Rodrigo Cavallazzi, Jose Bordon, Claudia Valdivieso, Joann Schulte, Ruth M Carrico, for the University of Louisville Pneumonia Study Group, Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality, *Clinical Infectious Diseases*, Volume 65, Issue 11, 1 December 2017, Pages 1806–1812, https://doi.org/10.1093/cid/cix647

99. Arnold, F.W., Reyes Vega, A.M., Salunkhe, V., Furmanek, S., Furman, C., Morton, L., Faul, A., Yankeelov, P. and Ramirez, J.A. (2020), Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes. J Am Geriatr Soc. doi:10.1111/jgs.16327

100. Ruiz M, Bottle A, Long S, Aylin P. Multi-Morbidity in Hospitalised Older Patients: Who Are the Complex Elderly?. PLoS One. 2015;10(12):e0145372. Published 2015 Dec 30. doi:10.1371/journal.pone.0145372

101. Skinner HG, Coffey R, Jones J, Heslin KC, Moy E. The effects of multiple chronic conditions on hospitalization costs and utilization for ambulatory care sensitive conditions in the United States: a nationally representative cross-sectional study. BMC Health Serv Res. 2016;16:77. Published 2016 Mar 1. doi:10.1186/s12913-016-1304-y

102. Dantas, I., Santana, R., Sarmento, J. et al. The impact of multiple chronic diseases on hospitalizations for ambulatory care sensitive conditions. BMC Health Serv Res 16, 348 (2016). https://doi.org/10.1186/s12913-016-1584-2

103. Buja, A., Rivera, M., De Battisti, E., Corti, M. C., Avossa, F., Schievano, E., … Ebell, M. H. (2018). Multimorbidity and Hospital Admissions in High-Need, High-Cost Elderly Patients. Journal of Aging and Health. https://doi.org/10.1177/0898264318817091

104. Amelia Harshfield, Kirsty Rhodes, James Brimicombe, Rupert Payne, Simon Griffin, The epidemiology of multimorbidity in primary care: a retrospective cohort studyAnna Cassell, Duncan Edwards, *British Journal of General Practice* 2018; 68 (669): e245-e251. DOI: 10.3399/bjgp18X695465

105. Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep. ePub: 6 April 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6914e4

Appendix: Methods, Models and the Data

Let U, V and W be the three sets representing the number of individuals in the USA who are having prior medical conditions: hypertension, cardiovascular diseases, and lung diseases as of the year 2020. Let $U_{65+}, V_{65+},$ and $W_{65+},$ be the corresponding sets of people who are aged 65 or above. Let $UV_{65+}, VW_{65+},$ and $WU_{65+},$ be the corresponding sets of people who are aged 65 or above and have pairs of medical conditions $(U, V), (V, W)$ and (W, U), respectively. There will be a smaller class of people who are 65 + and having all three medical conditions U, V and W, which we denote by UVW_{65+}. All these combinations of sets of prior medical conditions are defined below:

$$UV_{65+} = U_{65+} \cap V_{65+} =$$

$$\left\{ \begin{array}{c} \text{All the individuals } x\text{:age of } x \geq 65, \\ x \in U_{65+} \text{ and } x \in V_{65+} \end{array} \right\},$$

$$VW_{65+} = V_{65+} \cap W_{65+} =$$

$$\left\{ \begin{array}{c} \text{All the individuals } x\text{:age of } x \geq 65, \\ x \in V_{65+} \text{ and } x \in W_{65+} \end{array} \right\},$$

$$WU_{65+} = W_{65+} \cap U_{65+} =$$

$$\left\{ \begin{array}{c} \text{All the individuals } x\text{:age of } x \geq 65, \\ x \in W_{65+} \text{ and } x \in U_{65+} \end{array} \right\},$$

$$UVW_{65+} = U_{65+} \cap V_{65+} \cap W_{65+} =$$

$$\left\{ \begin{array}{c} \text{All the individuals } x\text{:age of } x \geq 65, \\ x \in U_{65+} \text{ and } V_{65+} \text{ and } x \in W_{65+} \end{array} \right\},$$

Let Ω be the set of all the sets of prior medical conditions, given by,

$$\Omega$$

$$= \{U_{65+}, V_{65+}, W_{65+}, UV_{65+}, VW_{65+}, WU_{65+}, UVW_{65+}\}$$
$$\text{------(A.1)}$$

Figure 4. COVID-19 patients (Y_{65+}) who are aged 65 and above and subsets of these patients with one or more of the prior medical conditions. Here $U_{65+}, V_{65+},$ and $W_{65+},$ are the subsets of COVID-19 patients people (Y_{65+}) with prior medical conditions, hypertension, cardiovascular disease, and lung diseases as of the year 2020. $UV_{65+}, VW_{65+},$ and $WU_{65+},$ are the corresponding subsets of patients with pairs of medical conditions (hypertension and cardiovascular diseases), (cardiovascular and lung diseases), and (lung diseases and hypertension), respectively. UVW_{65+} are the patients who have all three prior medical conditions within overall COVID-19 infected aged 65+, i.e. (Y_{65+}).

Once we have these sets of people with prior medical conditions, we will obtain the number of COVID-19 infected in the U.S. at time t, say, $Y_{65+}(t)$, by solving numerically coupled differential equations in (A.2),

$$\dot{X}_{<15}(t) = \begin{array}{l} -[\beta_{<15,<15}(t)X_{<15}(t)Y_{<15}(t) + \\ \beta_{15-64,<15}(t)X_{<15}(t)Y_{15-64}(t) \\ +\beta_{65+,<15}(t)X_{<15}(t)Y_{65+}(t)] \end{array}$$

$$\dot{X}_{15-64}(t) = \begin{array}{l} -[\beta_{<15,15-64}(t)X_{15-64}(t)Y_{<15}(t) + \\ \beta_{15-64,15-64}(t)X_{15-64}(t)Y_{15-64}(t) \\ +\beta_{65+,15-64}(t)X_{15-64}(t)Y_{65+}(t)] \end{array}$$

$$\dot{X}_{65+}(t) = \begin{array}{l} -[\beta_{<15,65+}(t)X_{65+}(t)Y_{<15}(t) + \\ \beta_{15-64,65+}(t)X_{65+}(t)Y_{15-64}(t) \\ +\beta_{65+,65+}(t)X_{65+}(t)Y_{65+}(t)] \end{array}$$

12

$$\dot{Y}_{<15}(t) = \begin{aligned}&[\beta_{<15,<15}(t)X_{<15}(t)Y_{<15}(t) + \\ &\beta_{15-64,<15}(t)\square_{<15}(t)Y_{15-64}(t) \\ &+\beta_{65+,<15}(t)X_{<15}(t)Y_{65+}(t)] \\ &-\gamma_{<15}(t)Y_{<15}(t)\end{aligned}$$

$$\dot{Y}_{15-64}(t) = \begin{aligned}&-[\beta_{<15,15-64}(t)X_{15-64}(t)Y_{<15}(t) + \\ &\beta_{15-64,15-64}(t)X_{15-64}(t)Y_{15-64}(t) \\ &+\beta_{65+,15-64}(t)X_{15-64}(t)Y_{65+}(t)] \\ &-\gamma_{15-64}(t)Y_{15-64}(t)\end{aligned}$$

$$\dot{Y}_{65+}(t) = \begin{aligned}&[\beta_{<15,65+}(t)X_{65+}(t)Y_{<15}(t) + \\ &\beta_{15-64,65+}(t)X_{65+}(t)Y_{15-64}(t) \\ &+\beta_{65+,65+}(t)X_{65+}(t)Y_{65+}(t) \\ &-\gamma_{65+}(t)Y_{65+}(t)\end{aligned}$$

------(A.2)

Here

$X_{<15}, X_{15-64}$, and X_{65+} represent susceptible people in the age-group <15, 15-64, 65+, respectively at time t. $Y_{<15}(t)$, $Y_{18-64}(t)$ and $Y_{65+}(t)$ represent those who are COVID-19 infected in the age-groups $<15, 15-64$, and 65+, respectively at time t. Here $\beta_{ij}(t)$ represent the average transmission rate from an infected in the age group j to an susceptible in the age group i. for $i, j = 15, 15-64$, and 65+, respectively at time t. The recovery rate parameter is $\gamma_i(t)$ for the age-groups <15, 15-64 and 65+ at the time t. Dynamic models without the age structure populations were used by us for the COVID-19 [12-13]. Age-structure deterministic models were also built for understanding other epidemics, such as, HIV/AIDS, bird flu, Hepatitis, other diseases and in population dynamics, see for example in [17-30]. The set of all transmission rate parameters, say, β_0, can be visualized as

$$\beta_0 = \begin{cases} \beta_{<15,<15} & \beta_{15-64,<15} & \beta_{65+,<15} \\ \beta_{<15,15-64} & \beta_{15-64,15-64} & \beta_{65+,15-64} \\ \beta_{<15,65+} & \beta_{15-64,65+} & \beta_{65+,65+} \end{cases}.$$

We have assumed $\beta_{ij} = \beta_{ji}$ for $i \neq j$ because the interacting populations will have same people and we do not have much information on the age-structure of the transmission rates. This will reduce $\square_0$ into a new set β given below:

$$\beta = \begin{cases} \beta_{<15,<15} & \beta_{15-64,<15} & \beta_{65+,<15} \\ \beta_{15-64,<15} & \beta_{15-64,15-64} & \beta_{65+,15-64} \\ \beta_{65+,<15} & \beta_{65+,15-64} & \beta_{65+,65+} \end{cases}$$

Based on the transmission values considered in our earlier articles on COVID-19 and further calibrating for the U.S. reported trend observed and model-based predictions for the periods March 1-14, 2020 and March 15-April 6, 2020, the β was considered for the medium range. Then the lower values and higher values were reduced to a fraction values of the medium range and the higher values increased to the same fraction above the medium range.

COVID-19 Cases With Combinations of Prior Medical Conditions

1.	U_{65+}	
2.	V_{65+}	
3.	W_{65+}	
4.	UV_{65+}	⎤
5.	VW_{65+}	⎬ Ω
6.	WU_{65+}	
7.	UVW_{65+}	⎦
⋮	⋮	
K.	( )	

Figure 5. COVID-19 cases with a list of all possible Individual and combinations of prior medical conditions. Suppose there are K items in that list. We have in this study considered $|\Omega|$ number of such

combinations with $|\Omega| < K$. We could extend the study with a larger $|\Omega|$ such that $|\Omega| \to K$ if we have the evidence of such data on prior medical conditions.

We will predict the number of individuals in each of the sets in Ω. Before we do this, for each element A in Ω, we assume

$$A \cap Y_{65+}(t) \neq \emptyset. \qquad \text{------(A.3)}$$

That is, there are at least one or more individuals in each of the sets A in Ω who is COVID-19 infected. Even if we violate the assumption by having one or more sets $B \neq A$ in Ω such that

$$B \cap Y_{65+}(t) = \emptyset, \qquad \text{------(A.4)}$$

then we provide model-based estimates for those sets which satisfy (A.3). From the U.S. COVID-19 data, we will obtain the fraction of cases who will have prior medical conditions for each element of Ω. These will form the initial values of each of the sets. We will also form monthly averages of these fractions. We simulate $\gamma_{65+}(t)$ values over the period April 7-June 30, 2020 and multiply the proportions of each of the sets of Ω after the time period of data collection is adjusted for monthly rates of infections within prior conditions. Suppose that $f_i(A)$ is the fraction of the set A of those who were infected with COVID-19 within the ith month, then, by computing

$$f_i(A)Y_{65+}(i), \qquad \text{------(A.4)}$$

for $i = 1,2,3$, we will obtain the monthly number of individuals who will likely acquire with prior medical condition A. Here $Y_{65+}(i)$ is the number of COVID-19 cases for the ith month. Note that

$$f_i(A)Y_{65+}(i) \in A \cap Y_{65+}(t)$$

for each $A \in \Omega$. Hence, $\sum_{i=1}^{3} f_i(A)Y_{65+}(i)$ represents the number of individuals within each prior medical conditions who need to be protected from being infected. These will assist in preventing death rates among such individuals.

From the magnitude of possible cases predicted for each of the sets in Ω, the Meyer wavelets were constructed. The Meyer wavelets $\psi(\omega)$ can be treated as infinitely differentiable functions within a certain domain. See details in [12-13,15]. The Meyer wavelets $\psi(\omega)$ and their accompanying function φ are given below

$\psi(\omega)$

$$= \begin{cases} \frac{1}{\sqrt{2\pi}}\sin\left(\frac{\pi}{2}\varphi\left(\frac{3|\omega|}{2\pi}-1\right)\right)e^{\frac{i\Box}{2}} & \text{if } 2\pi/3 < |\omega| < 4\pi/3 \\ \frac{1}{\sqrt{2\pi}}\cos\left(\frac{\pi}{2}\varphi\left(\frac{3|\omega|}{2\pi}-1\right)\right)e^{\frac{i\omega}{2}} & \text{if } 4\pi/3 < |\omega| < 8\pi/3 \\ 0 \text{ otherwise} \end{cases}$$

------(A.5)

Here $\varphi(x) = 0$ for $x < 0$, and

$$\varphi(x) = \begin{cases} x & \text{for } x \in (0,1) \\ 1 & \text{for } x > 1 \end{cases}.$$

------(A.6)

We plotted Meyer wavelets for the difference of the magnitude of the COVID-19 for the three-month period mentioned. These will help us in seeing the comparative dynamics of possible impact due to COVID-19 in terms of underlying conditions and hospitalizations (as shown in Figure 6). Wavelet theory is an improvement over traditional Fourier series expansions $f(x)$ defined either on $[0,2\pi)$ or on $[0,\pi)$ using *sin* and *cos* functions, where

$$f(x) = \sum_{0}^{\infty} a_n \cos nx + \sum_{1}^{\infty} b_n \sin nx,$$

------(A.7)

where a_n and b_n are coefficients of the series. Wevelets are shown to have immense help in several fields, including in epidemiology [15]. Further details and applications on wavelets can be seen elsewhere, for example in [31-35].

The entire methodology described can be repeated by applying other age group data as well as other prior medical conditions data.

Data:

Heart-related hospitalizations: The heart-related hospitalizations were estimated for 2016 data published in 2018 [36]. We have summed up the numbers for men and women in the age groups 65-74 and 75+ to obtain 65+ numbers, which is 1,432,000. Then we have assumed annual growth of these numbers at a rate of 0.7% to obtain the value of 1,472,519 for the year 2020. There were other studies that estimate burden of hospitalizations due to heart-related complications [37-44].

Hypertension: According to Older American's profile of 2017 published by ACL [44] (Administration of Community Living) within the department of health and human services, 58% of the US population aged 65+ are having hypertension. We have applied this percentage to the US population who are aged 65+ for the year 2020 [45] to obtain the number of individuals who are aged 65+ in the U.S. who have hypertension. We have applied hypertension percentage estimated for the year 2017 on the 2020 population (as there was no published estimate of hypertension percentage among persons aged 65+ for the year 2020). According to [46], the U.S. population estimate for the year 2020 is 331 millions of which 14.3% are aged 65+ [45]. This gives us the size of the U.S. population 65+ are 47.33 million and 58% of them, that is, 27.45 million with hypertension.

According to the data by the CDC, there are 33.5% of the persons aged 20+ in the U.S. who are taking medicine for hypertension during 2015-2016 [47]. Other studies indicated rise of hypertension among adults in the U.S. and in other countries [48-57].

Lung related illnesses: We have divided these broadly into two categories COPD (Chronic obstructive pulmonary disease) and pneumonia. According to [58], the global burden of hospitalizations due to COPD for aged 65+ is 14.2% and we do not have such statistics for the U.S. Applying this percentage of the US population aged 65+ gives us that there will be 6,721,286 people who are at risk of COPD in the U.S. in 2020. Among the COPD patients who are aged 45+, 51% admitted to the hospitals from an index ED visit [59]. Approximately 28.6% of the 45+ will be in the age group 65+ (as 14.3% of the total are in the age-group 65+). These fractions gives us that potential hospital visits due to pneumonia for the year 2020 will be an estimated 980,367.

According to the ambulatory and hospital care statistics survey in the US [60], there were 1.3 million visits to various emergency departments. We do not have information how many of these visits are by different individuals. An annual growth of 0.7% of those numbers as per the population growth in the country gives us an estimate of 1.59 millions for 2020. If we assume population proportion of aged 65+ to these numbers, then the anticipated hospital visits will be approximately 227,735 for the year 2020.

Overall lung-infections-related hospital visits will be 1,208,103.

Comorbidity of Hypertension and Cardiovascular Diseases: Individuals with hypertension have several comorbid conditions with heart related diseases in the U.S. and other countries [61-66]. For example, medical expenditure survey data of 2011-2014 [67] indicates, individuals with

16

hypertension have the following comorbid conditions: coronary heart disease (16.7%), heart rhythm disorders (6.0%), congestive heart failure (2.1%). This gives us 6,808,379 individuals who have comorbidity of hypertension and cardiovascular diseases in the U.S. for the year 2020.

Comorbidity of Cardiovascular Diseases and Lung diseases: Several studies have shown COPD with prevalence of comorbidity with cardiovascular diseases [67-71]. We consider the comorbidity prevalence 18% reported from the study [70] because the sample size they considered was one of the largest. The estimated comorbidity of COPD with cardiovascular diseases is 176,466 for the year 2020.

Other studies indicate pneumonia could worsen cardiac conditions [72-82]. In the study [83] it was found that 12% of the hospitalized with pneumonia had cardiovascular diseases. By applying this percentage of the CVD patients who are aged 65+ gives us 176,703 patients are at risk of hospitalizations in the year 2020.

Comorbidity of Hypertension and Lung diseases: The comorbidity due to COPD is one of the important and well-studied medical conditions [84-95]. The study [87] reports 28% of the COPD have comorbid condition of hypertension. A study by [85] considered 20,296 COPD patients to study comorbid conditions with diabetes, hypertension and cardiovascular diseases. Out of 437, 1680, 1168, 1670 patients aged 65-71, 72-75, 76-79, >80, the hypertension was recorded in 49.9%, 51.3%, 58%, 62.4%, respectively. A simple weighted average

gives us 56.5% of the COPD patients have hypertension as a comorbid condition. Applying these percentages on the COPD estimates of 2020 obtained above gives us 553,907 patients will have comorbid conditions of COPD and hypertension.

Hypertension has been found to be associated with pneumonia related hospitalizations in the US and several other countries [96-99]. We used 2.1% of the hypertensive individuals will have pneumonia during the year, which comes to 576,516 individuals.

Multiple morbidity among older patients: Several studies are available on multiple morbidlity data on older adults [100-104]. A study by Skinner et al [101] finds 30.1% of the elder population aged 65+ have 4 or 5 morbidities require hospitalization. We have applied these findings on the populations of hypertension and lung diseases combined and cardiovascular diseases and obtained an estimate of 783,486 for the year 2020.

Age-distribution of reported cases and model-based numbers in the U.S.: According to CDC's MMWR released on April 2, 2020 [105], out of the total COVID-19 cases reported until April 2, 2020 and whose age is known, there are 1.7% aged 18 or less. As of April 6, 2020, there are 367,004 COVID-19 cases reported in the U.S. Since the estimate for infected in the 0-15 age is not available, we use applied above percentage on the modeling based numbers obtained for the period. According to the same MMWR report, 76% of the infected persons are aged 18-64, and the remainder 22.3% are aged 65+. Our earlier model-based estimate as of April 6 had

561,005 COVID-19 cases in the age group 0+ and out of which 146,840 are in the age group 65+. These model-based numbers include reported and not reported. Assuming detected cases and recovered cases are under quarantine or taking precautions not to spread the disease to others, we have 561,005x1.7%-367,004x1.7% = 3298 persons aged 0-14 who will be contributing to the spread after April 6, if not taking any precautions. Similarly, 561,005x76%-367,004x76%=147,441 persons aged 15-64 who will be contributing to the spread and 561,005x22.3%-367,004x22.3%=43,262 persons aged 65+ will be contributing to the spread after April 6, 2020 if proper care is not taken. There are 51,374,510 individuals aged 0-14, 179,948,150 individuals aged 15-64 and 43,407,340 individuals aged 65+. Subtracting those individuals who were already detected from these age groups of susceptible individuals, we will have 51,368,270, 179,669,227 and 43,325,498 numbers of individuals remaining in the susceptible pool.

Break-up of underlying conditions among predicted COVID-19 cases: Once we have obtained three sets of model-based COVID-19 estimates (lower, medium, and higher) for the period April 7 – June 30, 2020, we have applied the percentages of three underlying conditions and multiple conditions available from [2,3]. We have adopted 4% of the COVID-19 will have all three underlying conditions. Since a detailed break-up of pairs of comorbidity percentages due to hypertension, cardiovascular and lung diseases was not available in the studies [2,3], we have adopted applied 37.8% for all three pairs combined. In the study [3], it was

reported that 37.6% of the patients reported having one or more conditions. In general, it is observed in various studies that 4% of the population will have multiple morbidities of 3 or above conditions (Table 2).

Meyer wavelets: From the predicted morbidities and comorbidities for the period April-June, 2020, the number of COVID-19 numbers predicted with prior medical conditions and predicted hospitalizations in Table 1 and Table 2, we have computed relative magnitudes of each medical condition with the total numbers, and constructed Meyer wavelets (Figure 3 and Figure 6).

Table 1. Estimated Prior Medical Condition or Combinations of Medical Conditions for Individuals aged 65+ in the U.S. in 2020 and during April 7 – June 30, 2020 who have risk of hospitalized if infected with COVID-19.

Medical Conditions and Combinations	Estimated number for the year 2020	Estimated number at risk for the Period April 7-June 30, 2020
Hypertension	27,453,140	9,151,047
Cardiovascular Diseases	1,472,519	490,840
Lung Diseases (COPD + pneumonia)	1,208,103	402,701
Hypertension and Cardiovascular Diseases	6,808,379	2,269,460
Cardiovascular and Lung Diseases	353,168	117,723
Hypertension and Lung Diseases	1,130,423	376,808
Hypertension, Cardiovascular and Lung Diseases	783,486	262,262

19

Table 2. Predicted COVID-19 Patients, Hospitalizations with and without ICU admissions among the U.S. Population aged 65+ during April 7 – June 30, 2020 who will have Prior Medical Condition or Combinations of Medical Conditions.

| Medical Conditions and Combinations of these	Model-based COVID-19 Patients, Hospitalizations (April – June, 2020)		
	Lower Estimates (Hospitalizations Non-ICU and ICU admissions)	Medium Estimates (Hospitalizations Non-ICU and ICU admissions)	Higher Estimates (Hospitalizations Non-ICU and ICU admissions)
Hypertension	25,259 (9,972 and 5,439)	75,590 (29842 and 16277)	346,665 (136856 and 74649)
Cardiovascular Diseases	17,674 (6,977 and 3,806)	52,892 (20881 and 11390)	242,570 (95762 and 52234)
Lung Diseases	13,465 (3,361 and 2,078)	40,294 (10057 and 6219)	184,793 (46122 and 28523)
Hypertension and Cardiovascular Diseases			
Cardiovascular and Lung Diseases (COPD+pneumonia)	13,082 (3,864 and 1,890)	39,149 (11565 and 5656)	179,540 (53036 and 25938)
Hypertension and Lung Diseases			
Hypertension, Cardiovascular and Lung Diseases	1392 (411 and 201)	4,165 (1230 and 602)	19,100 (5642 and 2759)

Figure 6. Meyer's wavelets of COVID-19 estimates for the period April-June, 2020 and Hospitalizations (a) COVID-19 estimates (b) Hospitalizations

21